Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
domingo, septiembre 20
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Myriad Genetics Inc
MYGN
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$3.89
-0.25
-6.04%
al cierre: Sep 18, 5:00 PM EST
$3.86
-0.03
-0.77%
After hour: Sep 18, 4:43 PM EST
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Myriad Genetics Financials
Myriad Genetics (MYGN) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Myriad Genetics Affirms FY2026 Sales Guidance of $770.000M-$790.000M vs $776.790M Est
Myriad Genetics (NASDAQ:MYGN) affirms FY2026 sales outlook from $770.000 million-$790.000 million to $770.000 million-$790.000 million vs $776.790 million estimate.
Benzinga Newsdesk
Myriad Genetics Stock Drops Sharply After Hours: What Investors Need to Know
Myriad Genetics stock fell after hours after weak Q2 results, lower guidance and an operating loss.
Tanya Rawat
PRO
Myriad Genetics Lowers FY2026 Sales Guidance from $860.000M-$880.000M to $770.000M-$790.000M vs $863.568M Est
Myriad Genetics (NASDAQ:MYGN) lowers FY2026 sales outlook from $860.000 million-$880.000 million to $770.000 million-$790.000 million vs $863.568 million estimate.
Benzinga Newsdesk
PRO
Myriad Genetics Q2 Adj. EPS $(0.25) Misses $(0.06) Estimate, Sales $190.700M Miss $206.029M Estimate
Benzinga Newsdesk
PRO
Myriad Genetics Affirms FY2026 Sales Guidance of $860.000M-$880.000M vs $864.099M Est
Myriad Genetics (NASDAQ:MYGN) affirms FY2026 sales outlook from $860.000 million-$880.000 million to $860.000 million-$880.000 million vs $864.099 million estimate.
Benzinga Newsdesk
PRO
Myriad Genetics Q1 Adj. EPS $(0.09) Misses $(0.07) Estimate, Sales $200.400M Miss $202.484M Estimate
Myriad Genetics (NASDAQ:MYGN) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.07) by 28.57 percent. This is a 200 percent decrease over losses of $(0.03) per share from
Benzinga Newsdesk
Privacy Manager